BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · IEX Real-Time Price · USD
25.03
-0.43 (-1.69%)
Apr 24, 2024, 4:00 PM EDT - Market closed
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 47.44, with a low estimate of 33 and a high estimate of 70. The average target predicts an increase of 89.53% from the current stock price of 25.03.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2024.
Analyst Ratings
The average analyst rating for BBIO stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 4 | 4 | 3 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 11 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $35 → $45 | Buy | Maintains | $35 → $45 | +79.78% | Mar 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $60 → $70 | Buy | Maintains | $60 → $70 | +179.66% | Mar 19, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $50 → $60 | Buy | Maintains | $50 → $60 | +139.71% | Mar 11, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $60 → $53 | Strong Buy | Maintains | $60 → $53 | +111.75% | Mar 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +87.77% | Mar 4, 2024 |
Financial Forecast
Revenue This Year
172.67M
from 9.30M
Increased by 1,756.07%
Revenue Next Year
196.86M
from 172.67M
Increased by 14.01%
EPS This Year
-3.31
from -3.95
EPS Next Year
-3.09
from -3.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 482.8M | 269.8M | 870.7M | 2.6B | 3.4B |
| Avg | 172.7M | 196.9M | 658.9M | 1.6B | 2.2B |
| Low | 12.6M | 113.8M | 220.5M | 726.2M | 1.5B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5,089.3% | 56.3% | 342.3% | 301.9% | 114.7% |
| Avg | 1,756.1% | 14.0% | 234.7% | 137.7% | 39.4% |
| Low | 35.9% | -34.1% | 12.0% | 10.2% | -6.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.66 | -1.93 | -0.75 | 3.81 | 4.76 |
| Avg | -3.31 | -3.09 | -1.97 | 3.70 | 4.62 |
| Low | -4.93 | -4.75 | -3.11 | 3.56 | 4.44 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 28.5% |
| Avg | - | - | - | - | 24.8% |
| Low | - | - | - | - | 19.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.